Welcome to our dedicated page for Viatris SEC filings (Ticker: VTRS), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
Viatris Inc. filings document the reporting record of a global healthcare company whose common stock trades on Nasdaq under VTRS. Form 8-K disclosures cover operating results, guidance and material events, including leadership transitions, restructuring actions from an enterprise-wide strategic review, bylaw amendments and shareholder-meeting matters.
Proxy statements describe board oversight, executive compensation, shareholder voting proposals, director nominations and governance practices. The filings also provide formal records for Viatris' capital return activity, strategic priorities, pipeline and product references, and the company's history as the combination of Mylan with Pfizer's Upjohn business.
Viatris Inc director James M. Kilts reported compensation-related equity transactions with no share sales. On March 6, 2026 he exercised 23,660 restricted stock units and 1,174.4921 dividend equivalent units, receiving 24,834.4921 shares of common stock. He also received a new grant of 15,890 restricted stock units that will vest on March 6, 2027. Following these acquisitions, he directly holds 161,257 shares of common stock and 15,890 unvested restricted stock units. All activity reflects awards under the Viatris Inc. 2020 Stock Incentive Plan.
Viatris Inc director Vivaldi Coelho Rogerio reported equity compensation activity involving restricted stock units (RSUs) and related common shares. On March 6, 2026, previously granted RSUs representing 23,660 shares of common stock vested in full and were exercised, along with 1,174.4921 dividend equivalent units that had accrued on those RSUs. These derivative securities converted into common stock, leaving no remaining balance from those specific RSUs or dividend units.
On the same date, the director received a new grant of 15,890 RSUs, each representing one share of Viatris common stock, which will vest on March 6, 2027. Following these transactions, the filing shows 46,526 shares of common stock held directly and a separate outstanding RSU award of 15,890 units scheduled to vest in 2027. The activity reflects routine vesting and a new equity award rather than any open-market buying or selling.
DAMELIO FRANK A reported acquisition or exercise transactions in this Form 4 filing.
Viatris Inc director Frank A. Damelio reported routine equity compensation activity. On March 6, 2026, previously granted restricted stock units (RSUs), including related dividend equivalent units, were fully settled into 26,031 shares of common stock that he now holds directly.
On the same date, he also received a new grant of 15,890 RSUs, each representing one future share of Viatris common stock. According to the award terms, these new RSUs will vest on March 6, 2027, reflecting ongoing director compensation rather than open-market buying or selling.
Viatris Inc director W. Don Cornwell increased his equity stake through routine equity awards and vesting. On March 6, 2026 he exercised 23,660 restricted stock units and 1,174.4921 dividend equivalent units into 23,660 and 1,175 shares of common stock, respectively. He also received a new grant of 15,890 restricted stock units that will vest on March 6, 2027.
Following these transactions, he directly holds 112,044 shares of Viatris common stock and 15,890 restricted stock units, reflecting compensation-related activity rather than open-market buying or selling.
Viatris Inc director Elisha W. Finney reported equity compensation activity, not open-market trading. On March 6, 2026, Finney exercised restricted stock units and related dividend equivalent units, acquiring 24,834.4921 shares of Viatris common stock through derivative conversions.
After these settlements, Finney directly held 62,667 shares of common stock. On the same date, Finney also received a new grant of 15,890 restricted stock units under the Viatris Inc. 2020 Stock Incentive Plan, which will vest on March 6, 2027.
Viatris Inc director David S. Simmons filed an amended ownership report showing indirect holdings of 684 shares of common stock held through family trusts. These include 13 shares in a trust for his benefit, 63 shares in a trust for him and his children, 522 shares in a trust for his spouse, and 86 shares in trusts for his children. The filing updates how these indirect, trust-held shares are reported rather than detailing any new stock purchase or sale.
Viatris Inc Chief Financial Officer Theodora Mistras reported equity award activity tied to previously granted restricted stock units. On March 4, 2026, restricted stock units and related dividend equivalent units granted on March 4, 2024 vested and were converted into shares of common stock.
She acquired 31,149 shares of common stock from RSUs and 2,935 shares from dividend equivalent units through exercises at $0.00 per share, and had 17,226 and 1,624 shares of common stock withheld at $14.71 per share to cover tax liabilities. After these transactions, she held 51,076 shares of Viatris common stock directly.
Viatris Inc Chief Commercial Officer Corinne Le Goff reported vesting and settlement of equity awards, along with related tax withholdings. On March 4, 2026, 36,720 restricted stock units granted on April 18, 2024 vested and converted into common stock, as did 3,053 dividend equivalent units. To cover tax liabilities tied to these vestings, 16,300 and 1,355 shares of common stock were withheld at $14.71 per share rather than sold on the open market. After these transactions, she directly owned 57,417 shares of Viatris common stock.
Viatris Inc officer Andrew Enrietti reported multiple equity award transactions. On March 3, 2026, he received a grant of 110,630 Performance Restricted Stock Units (PRSUs) and exercised the same number of PRSUs into common stock at a price of $0.00 per share.
On March 3 and March 4, 2026, restricted stock units and dividend equivalent units previously granted in 2023 and 2024 vested and were converted into common stock at $0.00 per share, while several blocks of common shares were withheld at prices of $14.89 and $14.71 per share to cover tax liabilities. After these transactions, his directly held common stock position was 208,308 shares.
Viatris Inc officer Paul Campbell reported multiple equity compensation events involving restricted stock units, performance RSUs, dividend equivalent units, and common stock. On March 3, 2026, he received 169,718 performance RSUs, which vested the same day and were converted into common shares, along with vested RSUs and related dividend equivalents from prior grants.
Common shares delivered from these vestings were partly withheld to satisfy tax liabilities, including 74,320 shares at $14.8900 per share and other smaller withholdings at similar prices, as noted in the footnotes. After the March 4, 2026 transactions, Campbell directly held 371,353 shares of common stock, plus 318 shares held indirectly through a 401(k) plan.